FDA cautions against use of malaria drugs in COVID-19 patients
(Reuters) – The U.S. Food and Drug Administration on Friday cautioned against the use of malaria drugs, hydroxychloroquine and chloroquine, in COVID-19 patients due to the risk of serious heart rhythm problems.
The agency said it was aware of increased use of these medicines through outpatient prescriptions and the drugs could cause abnormal heart rhythms and dangerously rapid heart rate. (bit.ly/3cHvepp)
Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Aditya Soni
Our Standards:The Thomson Reuters Trust Principles.
Source link